Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion

Journal of Vascular Surgery

Volumn 34, Issue 5, 2001, Pages 854-859

  Shortell, Cynthia K ^a   Queiroz, Rodolfo ^a   Johansson, Marcia ^a   Waldman, David ^a   Illig, Karl A ^a   Ouriel, Kenneth ^b   Green, Richard M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE DISEASE; ADULT; ARTICLE; CASE CONTROL STUDY; FEMALE; HUMAN; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY;

ACUTE DISEASE; ADULT; ARTERIAL OCCLUSIVE DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; PLASMINOGEN ACTIVATORS; RETROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035511971     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2001.118589     Document Type: Article

References (20)

1. Ouriel K, Shortell CK, DeWeese JA, Green RM, Francis CW, Azodo MV, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994;19:1021-30.
2. Ouriel K, Shortell CK, Azodo MVU, Guiterrez OH, Marder VJ. Acute peripheral arterial occlusion: predictors of success in catheter-directed thrombolytic therapy. Radiology 1994;193:561-6.
3. Ouriel K, Vieth FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998;338:1105-11.
4. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version [abstract]. J Vasc Surg 1998;26:517-38.
5. Ouriel K, Katzen B, Mewissen M, Flick P, Clair DG, Benenati J, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol 2000;11: 849-54.
6. Ouriel K, Kandarpa K, Scheurr DM, Hultquist M, Hodkinson G, Wallin B. Prourokinase vs. urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial. J Vasc Interv Radiol 1999;10:1083-91.
7. Lijnen RH, Collen D, Verstraete M. Thrombolytic agents. In: Verstraete M, Fuster V, Topol EJ, editors. Cardiovascular thrombosis: thrombocardiology and thromboneurology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998. p. 301-20.
8. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. JAMA 1999;282:2003-11.
9. Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol 1996;78(suppl 12A):2-7.
10. Brieger D, Topol EJ. Molecular biology and genetic engineering of plasminogen activators. In: Califf RM, editor. Continuing education series: thrombolytic therapy. New standards of care: part 1: the science of plasminogen activators. Am J Cardiol 1996. p. 16-22.
11. Meierhenrich R, Carlsson J, Seifried E, Pfarr E, Smolarz A, Neuhaus KL, et al. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency. Int J Cardiol 1998;65:57-63.
12. Meyerovitz M, Goldhaber SZ, Reagan K, Polak JF, Kandarpa K, Grassi CJ, et al. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial occlusions: a randomized controlled trial. Radiology 1990;175:75-8.
13. Hess H, Mietaschk A, von Bilderling P, Neller P. Peripheral arterial occlusions: local low-dose thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA). Eur J Endovasc Surg 1996; 12:97-104.
14. Koppensteiner R, Minar E, Ahmadi R, Jung M, Ehringer H. Lowdoses of recombinant human tissue-type plasminogen activator for local thrombolysis in peripheral arteries. Radiology 1988;168:877-8.
15. Verstraete M, Hess H, Mahler F, Mietaschk A, Roth FJ, Schneider E, et al. Femoro-popliteal artery thrombolysis with intra-arterial infusion of recombinant tissue-type plasminogen activator: report of a pilot trial. Eur J Vasc Surg 1988;2:155-9.
16. Graor RA, Olin JW, Bacharach M. Comparison of t-PA and urokinase for peripheral arterial thrombolysis. J Vasc Med Biol 1993;4:311-4.
17. Graor RA, Risius B, Young JR, Denny K, Beven EG, Geisinger MA, et al. Peripheral artery and bypass graft thrombolysis with recombinant human tissue-type plasminogen activator. J Vasc Surg 1986;3: 115-24.
18. Risius B, Graor RA, Geisinger MA, Zelch MG, Lucas FV, Young JR, et al. Recombinant human tissue-type plasminogen activator for thrombolysis in peripheral arteries and bypass grafts. Radiology 1986;160:183-8.
19. Semba CP, Murphy TP, Bakal CW. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. J Vasc Interv Radiol 2000;11:149-61.
20. Ouriel K. Retrospective evaluation of thrombolytic reperfusion of occlusions: the RETRO study. Presented at the 26th Annual Meeting of the Society of Cardiovascular Interventional Radiology; 2001 Mar 3-8; San Antonio, Texas.